Briefing
Whole genome–based ultrasensitive circulating tumor DNA clearance as a biomarker of exceptional outcomes with enfortumab vedotin and pembrolizumab in urothelial carcinoma: Preliminary real-world results.
Among evaluable patients, 11 (48%) achieved ctDNA clearance after a median of 3 EVP cycles and 12 (52%) had persistent positivity. The abstract states clearance correlated with exceptional clinical and radiographic outcomes, and persistent positivity identified residual or progressive disease. Median follow-up 13.8 months; 19 of 27 remained under surveillance, including 9 with metastatic disease.
- n: 27 patients, 118 plasma samples; single-institution retrospective
- Assay: Next Personal Dx tumor-informed whole-genome sequencing assay (up to 1,800 patient-specific variants; detection down to about 1 part per million), as stated in the abstract